Last update June 4, 2024


Decreased level of risk

New scientific evidences have driven the Apilam staff to update the level of risk associated to this product.
Former level of risk, which was Possibly safe. Probably compatible. Mild risk possible. Follow up recommended. Read the Comment., is now set to Safe. Compatible. Minimal risk for breastfeeding and infant.

Level of risk reviewed on June 4, 2024


Safe substance and/or breastfeeding is the best option.

Valsartan is an angiotensin II receptor antagonist (ARA) with actions similar to those of losartan. It is indicated in the treatment of hypertension, left ventricular dysfunction after myocardial infarction and in heart failure. Oral administration once or twice daily. 

Its pharmacokinetic data (high percentage of protein binding, large volume of distribution and moderately high molecular weight) explain the null passage into breast milk observed, below the limit of detection. (Falconi 2024)

In addition, its low oral bioavailability makes it difficult for it to pass into infant plasma from ingested breast milk, except in premature infants and the immediate neonatal period in which there may be greater intestinal permeability.

Dos lactantes cuyas madres tomaban sacubitril/valsartan no presentaron ningún problema. (Hale)


Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.

Other names

Valsartan in other languages or writings:


Main tradenames from several countries containing Valsartan in its composition:


Variable Value Unit
Oral Bioavail. 23 - 39 %
Molecular weight 436 daltons
Protein Binding 97 %
VD 0.24 l/Kg
pKa 8.15 -
Tmax 2 - 4 hours
6 - 9 hours
M/P ratio 0 -
Theoretical Dose 0 mg/Kg/d
Relative Dose 0 %


  1. Falconi S, Okimi A, Wesley S, Sethi P, Datta P and Krutsch K. The concentration of maternal sacubitril/valsartan transferred into human milk is negligible. Front. Public Health. 12:1389513. doi: 10.3389/fpubh.2024.1389513 Consulted on June 4, 2024 Full text (link to original source)
  2. Hale TW. Medications & Mothers' Milk. 1991- . Springer Publishing Company. Available from Consulted on April 10, 2024 Full text (link to original source)
  3. AEMPS. Valsartán. Ficha técnica. 2009 Full text (in our servers)
  4. MHRA. Valsartan. Drug Summary. 2009 Full text (in our servers)
  5. Tamargo j, Caballero R, Gómez R, Núñez L, Vaquero M y Delpón E. Características farmacológicas de los ARA-II. ¿Son todos iguales?. Rev Esp Cardiol Supl. 2006;6:10C-24C. 2006 Full text (in our servers)

Total visits


Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write us at

e-lactancia is a resource recommended by El Parto Es Nuestro of Spain

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM